Altuviiio® (antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl)
for Hemophilia

Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl) is a once-weekly recombinant factor VIII replacement therapy for hemophilia A. It can be used routinely to prevent bleeding or on-demand to treat acute bleeds. By replacing the missing coagulation factor VIII, Altuviiio supports effective blood clotting and reduces the risk of bleeding in patients with hemophilia A.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Hemophilia